PDF previews of the Pharma Outlook Q2 2023 report.

The data in this report was provided using a combination of benchmarking data around drug pipeline prioritization, partnerships, and acquisitions, and drug approvals. At the end of the report, we include a list of large impact drug catalysts through Q2 2023.

Related resources

Biopharma Deal-Making Roundup
APR 01, 2023
White paper

2022 Deal-Making Roundup

An overview of alliance, M&A, and financing deal activity across the worldwide biopharma, medical device, and in vitro diagnostics industries during 2022

Q3 2023 Outlook Report_resource-card-thumbnail
JUL 01, 2023

Q3 2023 Pharma Outlook Report

In this report, we cover catalysts from 29 drugs, devices, diagnostics, and deals expected to occur in Q3 2023.